Michaels, Alcoa, Horizon Acquisition, KemPharm and Ovid Therapeutics are five top gainers for Wednesday.

Novavax's loss widened on a big jump in revenue, as the biotech's CEO said it's making 'significant strides' toward bringing a COVID-19 vaccine to market.

Antibody drug cocktail casirivimab and imdevimab are allowed for use by people over age 12 with mild or moderate Covid-19.

Former FDA doc calls Azar's claim 'happy talk' as most experts expect a much longer time before widespread rollout of either a vaccine or effective treatment.

AstraZeneca has begun testing an antibody-based cocktail for the prevention and treatment of Covid-19. Moderna and Novavax are also moving forward with their respective vaccines.

Takeda Consumer Healthcare is a leading provider of over-the-counter medicines in Japan.

Plasma treatment would use antibodies of those who recovered from Covid-19.

Many experts remain uncertain about whether a vaccine from Novavax will be successful and beat the multiple other candidates to market.

Nikola, Silvercorp Metals, Renewable Energy Group, Trevena and Novavax are some of Monday's top gainers.

"We believe we have plenty of room on price value," Disney CEO Bob Chapek said of the group's streaming price hikes. "And we do not believe that there's going to be any meaningful on our churn as a result."

The theme park giant has been trying to make changes and that has caused some issues for its guests.

The pizza giant goes someplace pizza fans may not want to follow but Domino's, Pizza Hit, and Little Caesars don't sell this.